Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2752W HIGH $0.95
Volume
57.30 K
Value Traded
5.26 K
Short % Float
0.22%
-5.89%Week
-5.03%1 Month
-23.55%3 Month
-33.12%6 Month
-67.57%5 Year
-99.84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
45.03 M
EPS (TTM)
-0.08
P/E Ratio
-
Ent. Value
46.17 M
Total Shares
140.41 M
Float Shares
122.86 M
Insiders
12.43%
Institutions
57.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XTNT Catalyst Timeline
Dated clinical, regulatory and corporate events for Xtant Medical Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How XTNT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Xtant Medical Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every XTNT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC10% Owner | Sell | -56,004,974 | $0.42 | 04/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in XTNT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.8 % (14.3 %) | 34.36 M | 73.11 M |
XTNT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XTNT ranks across every disease it competes in
Competitive Position is a premium feature
See how XTNT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXTNT News
XTNTXtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market
Xtant Medical has formed an exclusive partnership with BioHorizons to distribute its allogeneic growth factor technology, OsteoFactor Pro™, branded as Prolifica™. This agreement aims to enhance access to advanced allograft technology in the dental and oral-maxillofacial markets across the U.S. and Canada. Both companies anticipate that this collaboration will create a sustainable channel for Prolifica™ and foster ongoing partnership opportunities.
Read more →XTNT▼ -28.3%on this news
Xtant Medical Reports Second Quarter 2026 Financial Results
Xtant Medical Holdings reported a significant decline in revenue for Q2 2026, totaling $23.0 million, down from $35.4 million in Q2 2025. This drop is attributed to the sale of non-core assets and changes in the reimbursement environment. Despite launching the Trivium™ Shaped and securing a distribution agreement with Dilon Technologies, the company faced a net loss of $9.4 million. The company has adjusted its full-year revenue guidance downward due to ongoing challenges.
Read more →XTNTXtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026
Xtant Medical Holdings, Inc. will release its financial results for Q2 2026 on August 11, 2026, before market opening. CEO Sean Browne and CFO Scott Neils will host a conference call at 8:30 AM ET to discuss the results. A replay of the call will be available on the company's website.
Read more →XTNTXtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference
Xtant Medical Holdings, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference from August 11-13, 2026. CEO Sean Browne, CFO Scott Neils, and COO Mark Schallenberger will present on August 11 at 2:00 pm ET. A live webcast will be available, with a replay accessible for 90 days.
Read more →XTNTXtant Medical Reports First Quarter 2026 Financial Results
Xtant Medical reported its first quarter 2026 financial results, revealing a revenue of $20.9 million, down from $32.9 million in Q1 2025. The company raised its full-year revenue guidance to $101-$105 million, bolstered by a new distribution agreement with Dilon Technologies. Despite a net loss of $3.1 million, Xtant's balance sheet has improved significantly.
Read more →XTNTXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
Xtant Medical Holdings, Inc. has announced that it will be releasing its financial results for the first quarter of 2026 on May 13, 2026. The announcement includes details of a conference call to be hosted by key executives, Sean Browne and Scott Neils, at 8:30 AM ET on the same day. This release is part of the company's regular updates to its stakeholders and aims to provide insights into its financial performance in the orthopedic market.
Read more →XTNTXtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
Xtant Medical has launched Trivium Shaped, an extension of its bone graft portfolio designed for surgical applications. This new product offers pre-shaped configurations to enhance consistency and efficiency in the operating room. The launch reflects Xtant's commitment to innovation in orthobiologics, utilizing PureLoc technology for improved graft performance.
Read more →XTNTXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant Medical has secured exclusive U.S. distribution rights for Dilon Technologies' HEMOBLAST® Bellows, a hemostatic product. This partnership aims to enhance Xtant's offerings and expand its market reach. The integration of Dilon's sales team is expected to bolster Xtant's commercial capabilities significantly. The companies believe this collaboration will address the needs of surgeons and patients effectively.
Read more →XTNTXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
Xtant Medical, in collaboration with the Montana Governor's Office of Community Service, announced support for the Threshold of Life Memorial. This memorial will honor organ, eye, and tissue donors and is set to be installed at the Montana State Capitol by Summer 2028. The initiative aims to raise awareness and inspire future donor registrations.
Read more →XTNTXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Xtant Medical reported a strong financial performance for 2025, with revenues reaching $133.9 million, a 14% increase from the previous year. The company achieved profitability and positive cash flow, bolstered by strategic divestitures and a focus on its biologics business. Looking ahead, Xtant anticipates continued growth in 2026 despite the cessation of some license revenues.
Read more →XTNTXtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Xtant Medical Holdings, Inc. will release its financial results for Q4 and the full year of 2025 on March 31, 2026. The announcement includes details for a conference call led by CEO Sean Browne and CFO Scott Neils. This event aims to provide insights into the company's performance and future outlook.
Read more →XTNTXtant Medical Finalizes Companion Spine Transactions
Xtant Medical has finalized transactions with Companion Spine, receiving $10.7 million related to the sale of its Coflex® assets and Paradigm OUS businesses. This payment brings the total purchase price for the divestitures to $21.4 million. The funds will help reduce long-term debt and increase liquidity, allowing Xtant to concentrate on its biologics business.
Read more →XTNTXtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
Xtant Medical Holdings, Inc. will participate in the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026. Key executives, including CEO Sean Browne, will present and engage in virtual one-on-one meetings with investors. A webcast of the presentation will be accessible starting February 2, 2026, and a replay will be available for 90 days.
Read more →XTNTXtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
Xtant Medical has launched its next-generation synthetic bone graft, nanOss Strata, designed to mimic human bone structure and enhance healing. Made from hydroxycarbonapatite, it offers improved bioactivity and osteoconductivity. The product is available in various forms and aims to improve surgical outcomes for patients. CEO Sean Browne emphasizes the company's commitment to innovation in regenerative medicine.
Read more →XTNTXTANT MEDICAL HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated financial information was derived from the historical consolidated fi
Xtant Medical Holdings, Inc. has released its unaudited pro forma condensed consolidated financial information following the divestiture of its subsidiary, Paradigm Spine GmbH, aimed at optimizing its business structure. The divestiture is expected to reduce the company's term loan significantly, potentially enhancing its financial position. Although the pro forma statements are meant for informational purposes only, they reflect adjustments due to the divestiture process. The report warns that these projections should not be construed as indicators of future financial results.
Read more →XTNTXtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
Xtant Medical Holdings has completed the sale of its Coflex® assets and Paradigm OUS businesses to Companion Spine for approximately $19.2 million. The transaction, which includes $11 million in cash and $8.2 million in seller financing, aims to strengthen Xtant's focus on its core biologics business. The proceeds will be used to reduce debt and enhance liquidity.
Read more →XTNTXtant Medical Reports Third Quarter 2025 Financial Results
Xtant Medical Holdings, Inc. reported a 19% increase in total revenue for Q3 2025, reaching $33.3 million. The company achieved positive net income of $1.3 million and adjusted EBITDA of $4.5 million, reflecting significant improvements from the previous year. Xtant reiterated its full-year revenue guidance of $131-$135 million, indicating expected growth of 11%-15% over FY24.
Read more →XTNT▲ +7.5%on this newsshared move
Xtant Medical Announces Commercial Launch of CollagenX™
Xtant Medical has announced the commercial launch of CollagenX™, a bovine collagen particulate product aimed at enhancing surgical wound closure. This addition to their biologics portfolio is designed to promote healing and prevent complications such as dehiscence and infections. The company emphasizes its commitment to innovation and improving patient outcomes through this new product.
Read more →XTNT▼ -8.6%on this newsshared move
Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025
Xtant Medical Holdings, Inc. announced that it will release its third quarter financial results for the period ending September 30, 2025, on November 11, 2025. The announcement includes details for a conference call hosted by the CEO and CFO at 8:30 AM ET the same day. Investors can also access a replay of the call on the company's website following the live event.
Read more →XTNTABHINAV (ABI) JAIN
Abhinav Jain has been appointed to the Compensation Committee and Nominating and Corporate Governance Committee. He has a strong background in investment management and currently serves on the boards of two specialty pharmaceutical companies. His financial expertise is expected to add significant value to the Board.
Read more →About Xtant Medical Holdings, Inc.
Headquarters664 CRUISER LANE, BELGRADE, MT, 59714
BIOPHARMAWATCH ELITE PLUS
Trade the next XTNT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime